St Jude makes US and EU progress with HF (heart failure) ICDs (implantable cardioverter defibrillator):
This article was originally published in Clinica
St Jude Medical has gained the green light from the US FDA to begin a clinical study of its implantable device for treating heart failure (HF). The Epic HF model V-338 implantable cardioverter defibrillator (ICD), which combines pacemaker therapy, defibrillation therapy, and left-heart stimulation, will be assessed in patients suffering from both heart failure and ventricular tachyarrhythmias. In a separate announcement, the St Paul, Minnesota firm said that it had CE-marked for sale in Europe another HF device from its Epic product line - the Epic HF model V-339 ICD. St Jude already markets in Europe a HF device called Genesis.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.